bioRxiv Science⌕ Search

bioRxiv · 10.1101/2022.10.10.511578

A key GPCR phosphorylation motif discovered in arrestin2-CCR5 phosphopeptide complexes

Abstract

The two non-visual arrestin isoforms, arrestin2 and arrestin3 recognize and bind hundreds of G protein-coupled receptors (GPCRs) with different phosphorylation patterns leading to distinct functional outcomes. The impact of phosphorylation on arrestin interactions has been well studied only for very few GPCRs. Here we have characterized the interactions between the phosphorylated CC chemokine receptor 5 (CCR5) and arrestin2. We detected several new CCR5 phosphorylation sites, which are necessary for stable complex formation with arrestin2. Crystal structures of arrestin2 in apo form and in complexes with CCR5 C-terminal phosphopeptides together with NMR spectroscopy, biochemical and functional assays revealed three phosphoresidues in a pXpp motif that are essential for the arrestin2 interactions and activation. The same phosphoresidue cluster is present in other receptors, which form stable complexes with arrestin2. We propose that the identified pXpp motif is responsible for robust arrestin2 recruitment in many GPCRs. An analysis of available sequences, structural and functional information on other GPCR*arrestin interactions suggests that a particular arrangement of phosphoresidues within the GPCR intracellular loop 3 and C-terminal tail determines arrestin2 and 3 isoform specificity. Taken together, our findings demonstrate how multi-site phosphorylation controls GPCR*arrestin interactions and provide a framework to probe the intricate details of arrestin activation and signaling. One-sentence summaryA structural and functional analysis of arrestin2 in apo form and complexes with several CCR5 phosphopeptides reveals key phosphorylation sites responsible for stable GPCR*arrestin interactions and their contributions to CCR5-arrestin2 function.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Isaikina, P., Petrovic, I., Jakob, R. P., Sarma, P., Ranjan, A., Baruah, M., Panwalkar, V., Maier, T., Shukla, A. K., Grzesiek, S.. 2022-10-12. A key GPCR phosphorylation motif discovered in arrestin2-CCR5 phosphopeptide complexes. https://doi.org/10.1101/2022.10.10.511578

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

A Deformulating Multi-Attribute SEC Method for Simultaneous Quantification of Total RNA, Conjugated Antibody, and Free Antibody in Targeted Lipid Nanoparticles

Targeted lipid nanoparticles (tLNPs) hold promise for improving cell- and tissue-selective delivery of therapeutic payloads but introduce analytical challenges associated with characterizing both encapsulated cargo and surface-associated targeting ligands within the same formulation. Conventional nucleic acid and protein assays can be affected by nanoparticle scattering, matrix interference, or a limited ability to distinguish conjugated antibody from free antibody. Here, we report an online deformulating size-exclusion high-performance liquid chromatography (SE-HPLC) method that enables simultaneous quantification of total RNA, conjugated antibody, and free antibody from 5 L of tLNP sample. Following injection, exposure to a mobile phase containing sodium dodecyl sulfate and isopropanol disrupts the nanoparticles, enabling chromatographic separation of RNA, conjugated antibody, and free (unconjugated) antibody while minimizing sample handling prior to analysis. RNA was quantified by UV260 detection, whereas antibody was quantified by UV280 or intrinsic fluorescence detection to maximize sensitivity. The method demonstrated linear response over the evaluated concentration ranges, spike recoveries of 88-122%, and precision below 5% relative standard deviation. Application to purified tLNP formulations demonstrated simultaneous assessment of total RNA and conjugated antibody content, while confirming the absence of detectable free antibody following purification. Together, these results establish online deformulating SE-HPLC as a practical multi-attribute analytical method for characterization of tLNPs, enabling concurrent assessment of total RNA concentration, conjugated antibody concentration, and free antibody concentration using standard HPLC instrumentation.

biophysics↗

Nanomechanical phenotyping uncovers a non-canonical smooth muscle-like hypercontractility program in lung squamous cell carcinoma myofibroblasts

Myofibroblast-like cancer-associated fibroblasts (myCAFs) drive the stiff, tumor-promoting microenvironment, yet their mechanical phenotype in non-small cell lung cancer (NSCLC) remains undefined. myCAFs from major NSCLC subtypes (lung adenocarcinoma (LUAD) and squamous cell carcinoma (LUSC)) were examined combining atomic force microscopy and traction force microscopy with molecular and signaling analyses. LUAD-myCAFs displayed canonical myofibroblast features, including elevated stiffness, traction forces, ROCK-MYPT1 signaling, and -SMA-rich stress fibers. Unexpectedly, LUSC-myCAFs amplified these nanomechanical features despite reduced ROCK-MYPT1 signaling and comparable -SMA levels. Instead, they exhibited a smooth muscle cell (SMC)-like contractile program characterized by enhanced SM-MHC(MYH11) expression colocalized with -SMA, ERK1/2-RLC hyperactivation, and DNA methylation reprogramming including SMC-contractility regulators. LUSC-myCAF hypercontractility was linked with reduced proliferative capacity and smaller intratumoral vessel lumens, consistent with the low CAF density and enhanced hypoxia patterns reported in LUSC. SMC markers were enriched and associated with adverse outcomes selectively in LUSC, highlighting the relevance of SMC-like myCAFs in LUSC progression. These findings unveil subtype-specific myCAF programs in NSCLC, and identify -SMA/SM-MHC(MYH11) myCAFs as key determinants of tumor mechanics, providing a rationale for the survival benefits of antihypertensive drugs targeting SMC hypercontractility. Moreover, they demonstrate that nanomechanical phenotyping can uncover translationally relevant myCAF phenotypes invisible to molecular profiling.

biophysics↗

Engineering Nanobody Conformational Switches

Conformational signaling is widely used in biology, but remains difficult to engineer into proteins. Here, we explore ligand-induced folding of nanobodies as a general strategy to generate conformational receptors for a broad range of target ligands. More specifically, we have generated partially unfolded nanobody variants that fold exclusively upon binding to their target ligand. To do so, we have introduced destabilizing mutations in the framework region, carefully tuning their stability while preserving molecular recognition. Given the high conservation of the framework across different nanobodies, this approach is broadly applicable to many other target ligands, which has enabled us to engineer conformational switches for three different important biomarkers and drugs: the pregnancy hormone chorionic gonadotropin, the cytokine tumor necrosis factor alpha, and the chemotherapy and immunosuppressant drug methotrexate. Another useful property of conformational signaling is that it can directly gate signal transduction, which we have leveraged to build an optical sensor for the quantitative detection of the pregnancy hormone in urine. Finally, conformational signaling introduces new mechanisms for the allosteric modulation of binding, which we have explored to control the affinity and dynamic range of the sensor. Our work thus establishes a rational strategy for engineering conformational signaling receptors with customizable properties and generalizable for many different target ligands.

biophysics↗